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ABSTRACT
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive
fibrosis of skin and multiple internal organs and severe functional and structural microvascular
alterations. SSc is considered to be the prototypic systemic fibrotic disorder. Despite currently
available therapeutic approaches SSc has a high mortality rate owing to the development of
SSc-associated interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH),
complications that have emerged as the most frequent causes of disability and mortality in SSc.
The pathogenesis of the fibrotic process in SSc is complex and despite extensive investigation
the exact mechanisms have remained elusive. Myofibroblasts are the cells ultimately
responsible for tissue fibrosis and fibroproliferative vasculopathy in SSc. Tissue myofibroblasts
in SSc originate from several sources including expansion of quiescent tissue fibroblasts and
tissue accumulation of CD34+ fibrocytes. Besides these sources, myofibroblasts in SSc may
result from the phenotypic conversion of endothelial cells into activated myofibroblasts, a
process known as endothelial to mesenchymal transition (EndoMT). Recently, it has been
postulated that EndoMT may play a role in the development of SSc-associated ILD and PAH.
However, although several studies have described the occurrence of EndoMT in experimentally
induced cardiac, renal, and pulmonary fibrosis and in several human disorders, the contribution
of EndoMT to SSc-associated ILD and PAH has not been generally accepted. Here, the
experimental evidence supporting the concept that EndoMT plays a role in the pathogenesis of
SSc-associated ILD and PAH will be reviewed.

Keywords: Systemic Sclerosis, Fibrosis, Interstitial Lung Disease, Pulmonary Fibrosis,
Pulmonary Arterial Hypertension, EndoMT, Endothelial cell, Myofibroblast.
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INTRODUCTION
Systemic Sclerosis (SSc) is a systemic autoimmune disease of unknown etiology
characterized by progressive fibrosis of skin and multiple internal organs, and severe functional
and structural fibroproliferative alterations in the microvasculature [1-3]. Although numerous
studies have examined the pathogenesis of SSc the exact mechanisms involved are not well
understood and have remained elusive [4-7]. However, it has been recognized that the most
serious clinical manifestations of the disease and its high mortality are the result of SScassociated-interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH). SScassociated ILD results from exaggerated and often progressive accumulation of fibrous
collagens and other extracellular matrix molecules in the lung parenchyma, whereas, SScassociated PAH is caused by functional alterations and structural fibroproliferative vasculopathy
affecting the small and medium sized pulmonary arterioles [8-12].
The cells ultimately responsible for the severe fibrotic process affecting the lung
parenchyma and for the fibroproliferative alterations in the small and middle size pulmonary
arterioles in SSc are the activated myofibroblasts [13-18]. Myofibroblasts are a unique
population of mesenchymal cells displaying a marked profibrotic cellular phenotype
characterized by the increased production of fibrillar type l and type lll collagens, initiation of
expression of α-smooth muscle actin (α-SMA), and reduction in the expression of genes
encoding ECM-degradative enzymes [19-23]. Myofibroblasts also acquire a motile behavior and
pronounced contractile properties, features that allow them to migrate to unaffected tissues and
to induce a progressive increase in tissue stiffness, a recently recognized potent profibrotic
stimulus [24,25]. Given the crucial role of myofibroblasts in the pathogenesis of organ-specific
and systemic fibrotic disorders there has been wide-ranging interest in the precise identification
of their origin [26-28]. Extensive research studies have shown that myofibroblasts originate from
diverse sources including expansion and activation of quiescent resident tissue fibroblasts [29],
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migration and tissue accumulation of bone marrow-derived circulating CD34+ fibrocytes [30-32],
or from epithelial cells or perivascular cells (pericytes) that have undergone a phenotypic
transition into mesenchymal cells [33-35]. More recent studies, however, have demonstrated
that another source of activated myofibroblasts are endothelial cells (EC) that have acquired a
mesenchymal phenotype through a process known as endothelial to mesenchymal transition
(EndoMT). During EndoMT EC lose their specific EC markers such as CD31/PECAM-1, von
Willebrand Factor (vWF), and VE-cadherin, and initiate the expression of mesenchymal cell
products including α–SMA, vimentin, and type I collagen [36,37]. Despite the demonstration of
the occurrence of EndoMT in numerous animal models of experimentally-induced cardiac,
pulmonary, and renal fibrosis [37-43], and several studies suggesting a role for EndoMT in the
pathogenesis of various human disorders [37,44-50], the possibility that EndoMT participates in
the development or progression of the fibrotic process or the fibroproliferative vasculopathy in
SSc has not been generally accepted.
Here, we will review the available experimental evidence that supports a role for
EndoMT in the pathogenesis of SSc-associated ILD and PAH. First, we will briefly review the
evidence that certain pathways that have been shown to participate in SSc-pathogenesis also
play a role in EndoMT as depicted in Figure 1. Secondly, we will discuss the occurrence of
EndoMT in experimental models of pulmonary fibrosis and pulmonary vascular disease. Finally,
we will review the available evidence that supports a role of EndoMT in various human
disorders and will discuss studies supporting the notion that the phenotypic change from EC to
activated myofibroblasts participates in the development of SSc-associated ILD and PAH.
1. ROLE OF PATHWAYS INVOLVED IN SSC PATHOGENESIS IN THE MOLECULAR
MECHANISMS OF ENDOMT.
1.1 The TGF-β pathway. Given the crucial role that TGF-β plays in the development of
tissue fibrosis and in the pathogenesis of numerous fibrotic diseases including SSc [51-54]
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several studies have investigated the role of this extended family of profibrotic growth factors in
the generation of myofibroblasts through EndoMT [55-58]. The detailed molecular events and
the intracellular cascades activated by TGF-β that result in the phenotypic change of EC into
mesenchymal cells have not been entirely elucidated. However, several studies have shown
that both Smad-dependent and Smad-independent pathways and numerous transcriptional
regulators such as Snail1, Snail2 (or Slug), Twist, and some members of Zeb family of proteins
are involved [55-59]. We recently examined the intracellular transduction pathways mediating
TGF-β-induced EndoMT in cultured murine lung EC.

We found that TGF-β induction of

EndoMT was mediated by the c-Abl kinase and by protein kinase c-δ and was associated with a
strong upregulation in the expression of Snail-1 [60].
1.2. Caveolin-1 (CAV1). CAV1, the main protein component of caveolae plays an
important role in the internalization, trafficking and degradation of TGF-β receptors and,
therefore, is involved in the regulation of TGF-β signaling and TGF-β-mediated fibrotic
responses [61,62]. Extensive studies in Cav1 knock out mice (Cav1-/-) showed that these mice
exhibited a remarkable phenotype characterized by extensive fibrotic tissue accumulation in
skin and lungs [63]. Following these observations several groups examined whether CAV1 may
play a role in human fibrotic disorders and described that CAV1 protein and gene expression
were markedly decreased in affected tissues from patients with SSc and SSc-associated ILD as
well as in lung tissues from patients with idiopathic pulmonary fibrosis [63-65]. Restoration of
CAV1 functional domains by supplementation with a caveolin scaffolding domain peptide or by
adenoviral-mediated expression of CAV1 corrected the profibrotic phenotype of SSc and IPF
cells in vitro [63-65] and in vivo in animal models of pulmonary fibrosis and PAH, including the
monocrotaline-induced model of PAH and the bleomycin-induced pulmonary fibrosis in mice
[64-66]. These studies, however, did not examine whether CAV1 was involved in EndoMT. To
address this point, we examined the role of CAV1 in EndoMT employing immunopurified EC
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isolated from lungs of Cav1-/-mice [67]. The results demonstrated the spontaneous occurrence
of EndoMT in

Cav1-/- pulmonary EC as evidenced by the constitutive expression of -SMA,

the high levels of production of type I collagen, and the high expression of the transcriptional
repressors Snai1 and Snai2, molecules previously shown to be upregulated in TGF-β1-induced
EndoMT. These observations demonstrated that EndoMT occurred spontaneously in Cav1-/mice in vivo and suggested that CAV1 deficiency, a molecular alteration that is a characteristic
feature of SSc cells, may participate in the development of the progressive tissue fibrosis and
proliferative vasculopathy in the disease through the establishment of EndoMT.
1.3. The role of endothelin-1 (ET-1) in EndoMT. Besides its crucial role in the
development of primary and secondary PAH, a growing body of evidence has implicated ET-1
as a participant in organ fibrosis and numerous studies have considered it as an important
trigger of the fibrotic process in SSc [68-70]. Although ET-1 is a major vasoactive peptide with
multiple effects on EC it is not known whether it is capable of inducing EndoMT. Recent studies
have examined whether ET-1 may also participate in the development of tissue fibrosis by
inducing EndoMT. In one study, Widyantoro, et al. [71] showed that EC-derived ET-1 promotes
cardiac fibrosis and heart failure in diabetic hearts through stimulation of EndoMT. In recent
studies from our group employing murine lung EC it was found that although ET-1 was not
capable of inducing EndoMT by itself it potentiated TGF-β-induced EndoMT. In subsequent
studies we showed that cultured CD31+ human EC cells also were induced to undergo EndoMT
in vitro when treated with ET-1 in the presence of TGF-β (Wermuth and Jimenez, unpublished
observations). In these studies we also demonstrated that ET-1 exerted potent synergistic
stimulation on TGF-β effects on EndoMT. A similar study employing immunopurified CD31
dermal EC from SSc patients and from normal individuals showed that TGF-β and ET-1 induced
EndoMT in normal and SSc-EC and that these effects involved the Smad pathway and were
blocked by the ET-1 receptor antagonist, macitentan [72]. The results of the studies with human
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EC demonstrate that ET-1 is capable of generating either by itself or in combination with TGF-β
activated tissue myofibroblasts through EndoMT. These studies also provide a novel
mechanism for ET-1 participation in the development of tissue fibrotic reactions.
1.4. Role of Notch and Hedgehog signaling pathways. The morphogens Notch and
Hedgehog play crucial roles during embryonic development [73-76]. Although in the adult these
pathways are tightly regulated, under some circumstances their aberrant activation may occur
leading to serious pathological consequences, including fibrotic diseases. Indeed, there are
numerous recent publications implicating alterations in Notch pathways in the pathogenesis of
SSc and other fibrotic diseases [77-79].
Although not extensively studied, it has recently become apparent that Notch pathways
may also participate in the regulation of EndoMT. The role of Notch signaling in EndoMT was
first described by Noseda, et al. [80] and it was suggested that the Notch pathway may be
crucial for heart valve and cardiac cushion development and/or vascular smooth muscle
differentiation [81,82]. In human microvascular EC, Notch and TGF-β synergistically stimulate
Snail expression and upregulate a subset of genes by recruiting Smad3 to Smad binding sites
[81-83]. However, while there is limited, although significant information, concerning the
interaction of Notch and TGF-β signaling in EndoMT, the potential role of Notch in SScassociated ILD and fibroproliferative vasculopathy has not been studied.
Another important pathway that has been shown to participate in the pathogenesis of
various fibrotic disorders is the Sonic Hedgehog (SHh) pathway [84-88]. Recently, an extensive
study [89] showed increased SHh expression in SSc affected tissues and demonstrated that
TGF-β increased its expression. Characterization of the cells displaying increased SHh
expression employing immunofluorescence for SHh epitopes showed intense EC staining in
affected SSc skin. Furthermore, SHh was capable of strong stimulation of fibroblast to
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myofibroblast transition with a potency similar to that of TGF-β [89]. However, the possibility
that SHh may be involved in EndoMT has not been examined.
1.5. Wnt pathway activation. Wnts comprise a multigene family of secreted
glycoproteins that play crucial roles during embryogenesis signaling through canonical and noncanonical pathways [90,91]. Following binding of Wnt ligands to their specific cell surface
receptor and co-receptors the activation of glycogen synthetase kinase (GSK)-3ß is inhibited
resulting in the accumulation of unphosphorylated β-catenin in the cytoplasm, followed by its
translocation into nucleus, and the activation of target genes. Secreted Frizzled-related proteins
(SFRP), Wnt inhibitory factors and other Wnt inhibitors such as Dkk-1 have been shown to
negatively modulate Wnt responses [90,91]. Recent studies showed that the Wnt/β-catenin
pathway is involved in the activation of numerous profibrotic steps in SSc pathogenesis [92-95].
Indeed, increased Wnt activation has been found in skin biopsies from SSc patients and it was
further shown that Wnt3a induced myofibroblast differentiation via Smad-dependent autocrine
TGF-β signaling promoting pathologic fibrogenesis [93]. A crucial role of β-catenin as a
mediation of the profibrotic effects of the Wnt pathway was also demonstrated [94]. It was also
shown that the Wnt pathway antagonists Dkk-1 and SFRP1 were epigenetically downregulated
in SSc cells [95]. Similar findings were also obtained in SSc-associated lung fibrosis with the
nuclear accumulation of β-catenin in activated fibroblasts present in fibroblastic foci in the lungs
of patients with SSc-associated ILD [96]. Despite these observations very few studies have
examined the role of Wnt pathway activation on the generation of activated myofibroblasts
through EndoMT. One recent study demonstrated that induction of canonical Wnt signaling
resulted in EndoMT pathway activation in cultured EC and in myocardial EC following
experimentally-induced myocardial infarction [97]. In contrast, two studies showed that the Wnt
inhibitor Dkk-1 enhanced EndoMT in aortic EC [98] and in human renal glomerular EC cultured
in a high glucose medium [99] results that indicate that further study is needed to conclusively
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determine the precise role of Wnt and of its inhibition on EndoMT-induced myofibroblast
generation.
1.6. Involvement of hypoxia in EndoMT. The transcription factor HIF-1 is the key
regulatory molecule responsible for the induction of a vast array of cellular and molecular
responses to hypoxia and has been implicated in various pathologic conditions [100-102].
Hypoxia-induced dysregulation of HIF-1 expression and activity has been implicated in the
pathogenesis of various fibrotic disorders including kidney and cardiac fibrosis [103,104]. The
mechanisms involved in HIF-1-induced fibrosis are very complex and include activation of a
vast array of profibrotic genes as shown in global gene expression changes in hypoxic hepatic
stellate cells [105], stimulation of expression of growth factors such as TGF-β and VEGF, and
induction of epithelial to mesenchymal transition [106-108]. However, the possibility that hypoxia
and HIF-1 may mediate some physiologic or pathologic responses through induction of
EndoMT has just begun to be explored. Indeed, two very recent studies showed that one
important downstream effect of HIF1- is the induction of EndoMT in human coronary EC and
that this effect may ultimately lead to development of cardiac fibrosis [109] and that HIF-1
mediated EndoMT during the development of radiation-induced pulmonary fibrosis [110].
2. DEMONSTRATION OF ENDOMT IN ANIMAL MODELS OF PULMONARY
FIBROSIS.
Although in the past EndoMT was believed to be a rare phenomenon confined to certain
stages of human embryonic development [36] numerous studies have described its occurrence
in various experimental models of fibrosis including cardiac, renal, and pulmonary fibrosis [3743]. One of the first studies to evaluate whether EC could represent a source of myofibroblasts
involved in the development of pulmonary fibrosis examined bleomycin-induced lung fibrosis in
double-transgenic mice with stable LacZ expression in EC [111]. In this setting any cells
originated from the EC lineage will be LacZ labeled. Morphological evaluation of lungs from the
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transgenic mice following endotracheal injection of bleomycin showed that the areas of fibrotic
involvement contained large numbers of LacZ-positive fibroblasts indicative of their endothelial
origin. To directly demonstrate the presence of EC–derived fibroblasts, lung fibroblasts from
either saline-injected control mice or from bleomycin treated mice were isolated and cultured.
LacZ detection revealed that approximately 16% of lung fibroblasts in the cultures from
bleomycin-treated mice were derived from EC. Immunocytochemical staining for type I collagen
and α-SMA showed that some cells from the bleomycin-treated mice expressed LacZ, type I
collagen, and α-SMA, demonstrating their EC origin. These findings conclusively showed that
lung EC could give rise to a substantial number of myofibroblasts through EndoMT in the
bleomycin-induced lung fibrosis model. Furthermore, the study demonstrated that the
phenotypic change was a permanently acquired trait. Another study examined the occurrence of
EndoMT in experimentally induced PAH. In this study PAH was induced in mice following
exposure to hypoxia and treatment with the antiangiogenic compound SU5416, a potent VEGF
receptor inhibitor [112]. The results showed that approximately 6% of pulmonary arterioles
displayed colocalization of vWF and -SMA indicative of the occurrence of EndoMT in vivo in
this animal model [112].
Despite the extensive experimental evidence supporting a role of EndoMT in the
pathogenesis of tissue fibrosis there have been some reports raising controversy as to whether
EndoMT was indeed a source of activated myofibroblasts contributing to the development of
fibrotic reactions in vivo [113,114]. However, a recent study using detailed endothelial lineage
tracing in transgenic mice with experimentally-induced renal fibrosis showed that from 10 to
20% of fibroblasts in the fibrotic kidneys arise from endothelial cells via EndoMT [42] in vivo,
and another study in experimentally induced cardiac fibrosis employing rigorous genetic cell
lineage tracing also showed that a population of cardiac interstitial fibroblasts were of EC origin
[115].
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3. DEMONSTRATION OF ENDOMT IN NON-PULMONARY HUMAN FIBROTIC
DISEASES.
Given the intense interest raised by the study of EndoMT in various animal models of
tissue fibrosis numerous studies have examined the occurrence of EndoMT in human
pathologic conditions [37,42]. Results from the rapidly growing literature about the possible
contribution of EndoMT to human disorders has provided strong support to the concept that
EndoMT may also play a role in the pathogenesis of SSc-associated ILD and PAH. Following
the pioneering description of Zeisberg et al. of the important role of EndoMT in the development
of cardiac fibrosis [38] numerous reports appeared describing the occurrence of EndoMT in
various human pathologic conditions [37,42]. For example, Bertram and collaborators
demonstrated that EndoMT played a significant role in the development of chronic kidney
disease in diabetes observations that were expanded to include other causes of chronic renal
failure [41]. In more recent studies, the possibility that EndoMT of portal vein endothelium via
TGF-β/Smad activation may also be involved in portal venopathy was examined [48]. The
results showed enhanced expression of phosphorylated Smad2 (pSmad2) in venous
endothelium of smaller portal veins in idiopathic portal hypertension, which was associated with
colocalization of EC and mesenchymal cell (myofibroblast) protein markers. The authors
concluded that the conversion of portal vein EC into cells expressing a myofibroblastic
phenotype may be responsible for exaggerated periportal-venous deposition of collagen and
other fibrous tissue proteins, and may represent the ultimate mechanism responsible for portal
venous obliteration in idiopathic portal hypertension. Other studies that described the
occurrence of EndoMT in human disorders include the demonstration of EndoMT in the process
of neointima formation in human vein graft tissues [47], the participation of EndoMT in the
severe heterotopic ossification occurring in the course of fibrodysplasia ossificans progressiva
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[49], and a prominent role in the development of intestinal fibrosis [45] and radiation induced
rectal fibrosis [50].
4. EVIDENCE SUPPORTING THE ROLE OF ENDOMT IN SSC-ASSOCIATED ILD
PULMONARY FIBROSIS AND PAH.
4.1. Demonstration of EndoMT in primary or in SSc-associated PAH. Arciniegas et
al. were among the first investigators to suggest a role of EndoMT in the pathogenesis of
chronic PAH [116]. Following this novel suggestion, two more recent studies implicated EndoMT
in the pathogenesis of PAH. The first study examined Primary PAH [117] and the second
studied PAH secondary to SSc [112]. In the first study Ranchoux and co-workers [117] applied
transmission electron microscopy, and correlative light and electron microscopy, providing
unequivocal ultrastructural-level evidence of ongoing dynamic EndoMT in lung tissue samples
from patients with primary PAH. Indeed, they demonstrated that typical EC identified by the
presence of Weibel-Palade bodies acquired expression of the myofibroblast-specific marker SMA, as well as, displayed invaginations into the neointima of the abnormal pulmonary
arterioles. In the second study, Good et al. [112], assessed EndoMT in the pulmonary arterioles
in lung tissues from patients with SSc-associated-PAH. Assessment of the cellular phenotype in
intimal and plexiform lesions from PAH lungs showed the unambiguous expression of
endothelial (CD31, CD34, VE-cadherin) and mesenchymal (-SMA) markers. A quantitative
assessment of the co-expression of vWF and -SMA indicated that up to 4% of pulmonary
arterioles in the lungs of patients with SSc-associated PAH displayed co-expression of EC and
mesenchymal cell markers. Furthermore, the protein and mRNA expression patterns confirmed
the notion of a key role of EndoMT in SSc-associated PAH pathology. The novel observations
described in these two studies provide conclusive evidence for the occurrence of EndoMT in
small and medium size arterioles of lung tissues from patients with both primary PAH and SScassociated PAH as discussed recently [118,119].
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4.2. Demonstration of EndoMT in lung tissues from patients with SSc-associated
ILD. We recently performed a study to examine the possibility that Endo-MT is involved in the
fibrotic process of SSc-associated ILD [120]. In this study lung tissues from six patients with
SSc and pulmonary fibrosis and 2 normal lung controls were examined by histopathology,
immunohistochemistry, and confocal laser microscopy for the simultaneous expression of
markers of EC (CD31 and vWF) and myofibroblasts (α-SMA or type I collagen).
Immunohistology studies showed expression of the EC marker CD31/PECAM in mesenchymal
cells embedded within the neointima of small pulmonary arteries as well as in the parenchymal
fibrotic areas in the six SSc lung specimens as illustrated in Figure 2. These observations
demonstrated for the first time the presence of cells carrying EC molecular markers removed
from the vessel endothelium and embedded within the fibrotic lung parenchyma in all SScassociated ILD samples examined. Co-expression of CD31 or vWF with the mesenchymal
markers, collagen type I or α-SMA was demonstrated employing confocal laser microscopy in
numerous EC lining the small and medium sized pulmonary arteries as illustrated for small
arterioles in Figure 3. These findings were not present in the small or medium sized arteries of
the normal lung tissues. The results demonstrated that EC co-expressing EC-specific and
myofibroblastic cell markers are present in the endothelium of small pulmonary arteries from
patients with SSc-associated pulmonary fibrosis and suggest that mesenchymal cells of
endothelial origin are likely to be responsible for the production and accumulation of
subendothelial fibrotic tissue in the affected vessels that in turn results in their luminal
obliteration.
These observations were confirmed by an extensive assessment of the differences in
gene expression patterns between microvascular EC isolated from normal lungs compared to
microvascular EC isolated from lungs from patients with SSc-ILD. The gene expression
assessment of immunopurified CD31+/CD102+ EC obtained from lung tissues from two patients
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with SSc-associated ILD compared to the average gene expression of immunopurified
CD31+/CD102+ EC from two control lungs is shown in Figure 4. The results demonstrated a
very strong expression of COL1A1 and COL3A1 in the CD31+/CD102+ purified EC from lungs
from SSc patients and these values were up to 21 times and 26 times higher, respectively, than
the expression of the same collagen genes in CD31+/CD102+ EC purified from the normal
control lungs. The expression of FN1 and ACTA2 (-SMA), other profibrotic genes such as
TGFB1 and CTGF, and that of several EndoMT-related genes such as SNAI2 and TWIST was
also substantially increased in the CD31+/CD102+ EC from the lungs of SSc patients. Thus, we
believe that the results of the extensive study performed in lung tissues from patients with SScassociated ILD provide conclusive evidence for the occurrence of EndoMT during the fibrotic
process affecting the lungs in SSc.
CONCLUDING REMARKS.
The results of the various studies reviewed here including evidence from experimental
animal models of tissue fibrosis and from several studies with tissues from patients with SScassociated ILD and PAH certainly indicate that the participation of EndoMT in these processes
should no longer be considered a myth but it is, indeed, a reality. Furthermore, the results of
these studies also suggest that greater understanding of the molecular mechanisms involved in
EndoMT and its pharmacological modulation may represent a novel therapeutic approach for
devastating effects and the high mortality of the SSc-associated tissue fibrosis and
fibroproliferative vasculopathy complications that currently do not have effective therapies.
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Figure Legends.
Figure 1. Signaling pathways involved in SSc pathogenesis that may also play a role in
EndoMT.
The diagram shows the TGF-β, ET-1, NOTCH, and Wnt pathways, as well as, other putative
pathways such as cellular stress and hypoxia that may participate in the EndoMT process and
may be involved in SSc pathogenesis. One central pathway is initiated following TGF-β-binding
and subsequent activation of the ALK-1-mediated Smad-independent TGF- pathway.
Activation of this pathway causes phosphorylation of GSK-3 mediated by PKC-δ and the c-Abl
non-receptor kinase. Phosphorylation of GSK-3 at serine 9 (ser9) causes its inhibition which
then allows Snail-1 to enter the nucleus. Nuclear accumulation of Snail-1 results in marked
stimulation of Snail-1 expression which then leads to acquisition of the myofibroblast phenotype
with stimulation of -SMA expression. The inhibition of GSK-3 ser9 phosphorylation by specific
inhibition of PKC-δ or c-Abl activity allows GSK-3β to phosphorylate Snail-1 targeting it for
proteosomal degradation and thus, effectively abolishes the acquisition of the myofibroblastic
phenotype and the fibrotic response. ET-1 effects appear to be mediated by a synergistic
stimulation of TGF-β-induced EndoMT involving the canonical Smad pathways although the
possibility of a direct stimulation of EndoMT by ET-1 has also been suggested. Other pathways
such as those involving Wnt, NOTCH, hypoxia and cellular stress responses may also
participate although the molecular events have not been fully elucidated. Modified from Ref.
119.

Figure 2. Histopathology and immunohistology of SSc-associated ILD lung tissues.
A. A small artery in the lung of a patient with SSc-associated ILD shows severe narrowing of the
vessel lumen with accumulation of elongated mesenchymal cells and large amounts of fibrous
tissue in the subendothelial intimal space. B. Immunohistochemical staining of the same tissue
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for the endothelial cell specific antibody marker CD31. Note the presence of CD31 positive cells
in the subendothelial space besides their expected endothelial location. C. Lung tissue from
another patient showing two cells bearing the EC-specific CD31 marker embedded within the
neointimal tissue removed from the endothelium, and a CD31-positive cell cluster within the
fibrotic lung parenchyma. D-F. CD31 immunohistological staining of lung tissues from three
additional SSc patients showing similar findings. (Reproduced from Ref. 120 with permission).

Figure 3. Confocal microscopy staining for vWF and α-SMA of a small arteriole in the
lung of a patient with SSc-associated ILD.
Staining for vWF is shown in green; staining for α-SMA is shown in red, and co-expression of
vWF and α-SMA is shown in yellow in the merged image. All EC (vWF-stained) present within
the endothelium and subendothelial tissue express the mesenchymal cell marker -SMA.
(Reproduced from Ref. 120 with permission).

Figure 4. Quantitative PCR assessment and Western blot analysis of expression levels
of selected genes and proteins in CD31+/CD102+ lung EC from SSc-associated ILD.
Quantitative PCR of two different preparations of CD31+/CD102+ EC from lungs of two SSc
patients or from normal lungs analyzed in duplicate. Shown are transcript measurements for
interstitial collagen genes (COL1 and COL3), fibronectin 1 (FN1), α-SMA (SMA), EC-specific
genes (COL4A1, VE-cadherin, vWF and VEGF), profibrotic genes (TGF-β1 and CTGF), and
EndoMT-related transcription factors (SNAI2, and TWIST1). Fold change in CD31+/CD102+ EC
from each of the SSc lungs (SSc1 and SSc2) compared to the average levels of the
CD31+/CD102+ EC from the two normal lungs. (Reproduced from Ref. 120 with permission).
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